UZ-UCSF’s Seke South CRS has been officially selected as a protocol specific site by the US National Institutes of Health’s HIV Vaccine Trials Network (HVTN). The HVTN’s mission is to facilitate the process of testing preventative vaccines against HIV/AIDS and is a global leader in vaccine development. These will be the first ever HIV-related vaccine clinical trials conducted in Zimbabwe.
Seke South CRS is located in Chitungwiza, approximately 30km south of Harare and has successfully implemented clinical research under the Microbicide Trials Network (MTN). Plans are currently underway to expand site laboratory and pharmacy infrastructure to further support the addition of this network in this site’s portfolio of collaborators. It is anticipated that infrastructural development should be complete in 2014, with the first protocol expected to start in spring 2015.
Site implementation of HVTN will be led by Z.M. Chirenje, MD, FRCOG, UZ-UCSF Executive Director, and Senior Medical Officer, Lynda Stranix-Chibanda, MBChB, MMed.